Previous studies have demonstrated potential connections between ATRX/DAXX, H3-3A (encoding for H3.3 histone variant) mutations and ALT use, especially in oligodendrogliomas, medulloblastomas, neuroblastomas and GBM [27,28,29]. The gene discussed is ATRX; the disease is neuroblastoma.